2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1333 Phase 3 trial design of vmx-C001 vs usual pharmacological care in patients taking factor xa inhibitors who require urgent surgery/procedures (EQUILIBRIX-S)

Jeffrey Weitz, MD, G. Morgan Jones, PharmD, FCCM, FNCS2, Andres Brainsky, MD3, Gerard Short, MBBS, MBA, MRCP4
1 McMaster University, Hamilton, Ontario, Canada
2 CSL Behring, King of Prussia, Pennsylvania, United States
3 CSL Behring, King of Prussia, Pennsylvania, United States
4 VarmX B.V., Leiden, Netherlands

Background and Significance: Urgent surgery or invasive procedures in patients receiving oral factor Xa inhibitors (FXaI) may be required before clinically relevant anticoagulant activity has resolved. Current pharmacological options to restore coagulation in these patients include prothrombin complex concentrates (PCC), which are used off-label for FXaI-associated bleeding and urgent surgery/procedures, and andexanet alfa, a target-specific reversal agent with limited availability in some regions and no licensed role in surgery/procedures.

VMX-C001 is an investigational human, recombinant modified coagulation factor X (FX) designed to restore thrombin generation by bypassing FXaI activity without binding to or neutralizing these agents. The molecule retains the core structure of endogenous human FX and includes an engineered 99-loop modification intended to impair FXaI binding while preserving FX function. In pre-clinical studies, VMX-C001 restored thrombin generation in plasma and in non-human primates exposed to apixaban, rivaroxaban, or edoxaban. In a separate model using rivaroxaban, VMX-C001 reduced bleeding time and blood loss in a cynomolgus monkey liver injury model.

Phase 1 studies in healthy adult participants found that VMX-C001 bypassed FXaI-associated anticoagulation, as assessed by dilute prothrombin time (dPT) and dilute Russell's viper venom time (dRVVT). VMX-C001 shifted thrombin generation parameters toward baseline across apixaban, rivaroxaban, and edoxaban and showed dose-proportional pharmacokinetics with a half-life of about 24-30 hours. Administration of VMX-C001 was not associated with thrombotic events, serious drug-related adverse events or treatment-related increases in prothrombotic markers. A separate Phase 1 study showed that the anticoagulant activity of heparin was preserved after VMX-C001 administration. Evaluation of different administration times across separate Phase 1 studies showed that a 10-second intravenous (IV) injection produced exposure and safety profiles comparable to both 2-min and 5-min infusion times. These findings support evaluation of VMX-C001 as a rapid coagulation restoration strategy for FXaI-treated patients requiring urgent surgery/procedures in the Phase 3 trial.

 Study Design and Methods: EQUILIBRIX-S (NCT07288489) is an ongoing Phase 3, prospective, randomized, open-label, multicenter trial comparing VMX-C001 with usual pharmacological care in adults receiving FXaIs who require urgent surgery/procedures, with or without heparin. The trial is enrolling across multiple regions. Eligible participants must have significant residual FXaI exposure, defined as surgery/procedure within 15 hours of the last known FXaI administration, a documented FXaI level ≥75 ng/mL within 2 hours before the procedure, or a heparin-calibrated anti-FXa assay ≥0.85 IU/mL. Key exclusions include known bleeding risk unrelated to FXaI exposure, recent non-FXa anticoagulant or heparin use within protocol-specified windows, and prohibited concomitant medications before randomization. Participants are randomized 1:1 to VMX-C001 150 mg as a 10-second IV injection at least 5 minutes before the procedure or to usual pharmacological care, defined as site-standard, pre-documented pharmacological treatment with a prespecified absolute dose of PCC, activated PCC, or andexanet alfa. The primary efficacy endpoint is the proportion of participants with good or excellent hemostatic efficacy during the procedure, determined by blinded adjudication committee (EAC) assessment of observed versus expected intra-procedural blood loss. Key secondary and exploratory endpoints include pre-procedure changes in dPT and dRVVT, actual-to-expected blood loss, bleeding severity using the Validated Intraoperative Bleeding (VIBe) scale, pre-procedural blood loss in participants with active bleeding, thrombin generation and clotting parameters, heparinization assessments in heparin-treated participants, and post-procedural blood loss. Safety and tolerability are assessed through Day 28, including bleeding, thrombosis, injection-site reactions, and anti-VMX-C001 or anti-FX antibodies.  

Andres Brainsky, MD: CSL Behring - Stock (publicly traded); CSL Behring - Current Employment